• 1
    Nicolson GL. Cancer progression and growth: relationship of paracrine and autocrine growth mechanisms to organ preference of metastasis. Exp Cell Res 1993; 204: 17180.
  • 2
    Pinon P, Wehrle-Haller B. Integrins: versatile receptors controlling melanocyte adhesion, migration and proliferation. Pigment Cell Melanoma Res 2011; 24: 28294.
  • 3
    Kuphal S, Bauer R, Bosserhoff AK. Integrin signaling in malignant melanoma. Cancer Metastasis Rev 2005; 24: 195222.
  • 4
    Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392401.
  • 5
    Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 23952.
  • 6
    Straussman R, Morikawa T, Shee K et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487: 5004.
  • 7
    Halaban R, Rubin JS, Funasaka Y et al. Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells. Oncogene 1992; 7: 2195206.
  • 8
    Otsuka T, Takayama H, Sharp R et al. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res 1998; 58: 515767.
  • 9
    Recio JA, Merlino G. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene 2002; 21: 10008.
  • 10
    Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol 2001; 491: 369402.
  • 11
    Houghton AN, Mintzer D, Cordon-Cardo C et al. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A 1985; 82: 12426.
  • 12
    Cheung NK, Cheung IY, Ostrovnaya I, Kushner BH. Reply to L. Moreno et al. J Clin Oncol 2013; 31: 6501.
  • 13
    Furukawa K, Hamamura K, Ohkawa Y, Ohmi Y. Disialyl gangliosides enhance tumor phenotypes with differential modalities. Glycoconj J 2012; 29: 57984.
  • 14
    Yoshida S, Fukumoto S, Kawaguchi H, Sato S, Ueda R, Furukawa K. Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res 2001; 61: 424452.
  • 15
    Hamamura K, Furukawa K, Hayashi T et al. Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells. Proc Natl Acad Sci U S A 2005; 102: 110416.
  • 16
    Nagata Y, Yamashiro S, Yodoi J, Lloyd KO, Shiku H, Furukawa K. Expression cloning of beta 1,4 N-acetylgalactosaminyltransferase cDNAs that determine the expression of GM2 and GD2 gangliosides. J Biol Chem 1992; 267: 120829.
  • 17
    Haraguchi M, Yamashiro S, Yamamoto A et al. Isolation of GD3 synthase gene by expression cloning of GM3 alpha-2,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody. Proc Natl Acad Sci U S A 1994; 91: 104559.
  • 18
    Miyazaki H, Fukumoto S, Okada M, Hasegawa T, Furukawa K. Expression cloning of rat cDNA encoding UDP-galactose:GD2 beta1,3-galactosyltransferase that determines the expression of GD1b/GM1/GA1. J Biol Chem 1997; 272: 247949.
  • 19
    Fukumoto S, Miyazaki H, Goto G, Urano T, Furukawa K. Expression cloning of mouse cDNA of CMP-NeuAc:Lactosylceramide alpha2,3-sialyltransferase, an enzyme that initiates the synthesis of gangliosides. J Biol Chem 1999; 274: 92716.
  • 20
    Furukawa K, Ohkawa Y, Yamauchi Y, Hamamura K, Ohmi Y, Furukawa K. Fine tuning of cell signals by glycosylation. J Biochem 2012; 151: 5738.
  • 21
    Dippold WG, Lloyd KO, Li LT, Ikeda H, Oettgen HF, Old LJ. Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci U S A 1980; 77: 61148.
  • 22
    Ohkawa Y, Miyazaki S, Hamamura K et al. Ganglioside GD3 enhances adhesion signals and augments malignant properties of melanoma cells by recruiting integrins to glycolipid-enriched microdomains. J Biol Chem 2010; 285: 2721323.
  • 23
    Ohkawa Y, Miyazaki S, Miyata M, Hamamura K, Furukawa K. Essential roles of integrin- mediated signaling for the enhancement of malignant properties of melanomas based on the expression of GD3. Biochem Biophys Res Commun 2008; 373: 149.
  • 24
    Hamamura K, Tsuji M, Hotta H et al. Functional activation of Src family kinase yes protein is essential for the enhanced malignant properties of human melanoma cells expressing ganglioside GD3. J Biol Chem 2011; 286: 1852637.
  • 25
    Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ. GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med 1982; 155: 113347.
  • 26
    Nakano J, Raj BK, Asagami C, Lloyd KO. Human melanoma cell lines deficient in GD3 ganglioside expression exhibit altered growth and tumorigenic characteristics. J Invest Dermatol 1996; 107: 5438.
  • 27
    Hamamura K, Tsuji M, Ohkawa Y et al. Focal adhesion kinase as well as p130Cas and paxillin is crucially involved in the enhanced malignant properties under expression of ganglioside GD3 in melanoma cells. Biochim Biophys Acta 2008; 1780: 5139.
  • 28
    Natali PG, Nicotra MR, Di Renzo MF et al. Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br J Cancer 1993; 68: 74650.
  • 29
    Cruz J, Reis-Filho JS, Silva P, Lopes JM. Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas. Oncology 2003; 65: 7282.
  • 30
    Beuret L, Flori E, Denoyelle C et al. Up-regulation of MET expression by alpha-melanocyte-stimulating hormone and MITF allows hepatocyte growth factor to protect melanocytes and melanoma cells from apoptosis. J Biol Chem 2007; 282: 141407.
  • 31
    Recio JA, Merlino G. Hepatocyte growth factor/scatter factor induces feedback up-regulation of CD44v6 in melanoma cells through Egr-1. Cancer Res 2003; 63: 157682.
  • 32
    Gaggioli C, Deckert M, Robert G et al. HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1. Oncogene 2005; 24: 142333.
  • 33
    Cazet A, Bobowski M, Rombouts Y et al. The ganglioside G(D2) induces the constitutive activation of c-Met in MDA-MB-231 breast cancer cells expressing the G(D3) synthase. Glycobiology 2012; 22: 80616.
  • 34
    Kankuri E, Cholujova D, Comajova M et al. Induction of hepatocyte growth factor/scatter factor by fibroblast clustering directly promotes tumor cell invasiveness. Cancer Res 2005; 65: 991422.
  • 35
    Wilson TR, Fridlyand J, Yan Y et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487: 5059.
  • 36
    Li G, Schaider H, Satyamoorthy K et al. Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 2001; 20: 812535.
  • 37
    Miyazaki H, Shiku H, Furukawa K. Differential effects of a murine monoclonal antibody reactive with the disialylgalactosyl residue on the growth of melanoma cells and T cell activation. Int J Oncol 1996; 9: 2415.